Aptamer Group
plc
("Aptamer", the "Company" or
the "Group")
Patent submission for
Optimer® binders in cosmetic products
Aptamer Group plc (AIM: APTA), the
developer of novel Optimer® binders to enable innovation
in the life sciences industry, today announces that it has filed a
patent application to protect the recently developed Optimer binder
sequences for novel applications in fast moving consumer goods
generated as part of its partnership with Unilever.
The patent was submitted on 28 March
2024. Submission of this patent application reinforces the ongoing
commercial protection of Aptamer Group's leading technology
position in the development of high-performance binders.
Aptamer Group developed the binders
as part of a fee-for-service project and has continued to support
Unilever in validating the functionality of the binders both
in-house at Aptamer Group and within Unilever's own labs.
Submission of the patent at this stage establishes a 'priority
date' for the binder sequences, giving Aptamer Group precedence for
the protection of the intellectual property while allowing
commercial negotiations to continue.
Dr
Arron Tolley, Chief Technical Officer of Aptamer Group,
said: "The submission of this patent
is an important milestone for Aptamer Group and supports the next
stages of commercial advancement with Unilever. We are really
pleased with the work performed by our scientists and those at
Unilever over the past few months to demonstrate the use of these
Optimer binders and their suitability for application in fast
moving consumer goods. We will continue to work closely with the
team at Unilever to support their use of the binders in this
exciting new application."
Dr
Samantha Samaras, Senior Vice President of R&D at Unilever,
said: "Over the past 12 months we
have been working with the excellent team at Aptamer Group to
discover, develop and exploit their Optimer binders for cosmetic
applications. We look forward to continued collaboration in this
exciting applications space."
- ENDS
-
For further information, please
contact:
Aptamer Group plc
Steve Hull
|
+44 (0) 1904 217
404
|
SPARK Advisory Partners Limited - Nominated
Adviser
Andrew Emmott / Adam
Dawes
|
+44 (0) 20 3368
3550
|
Turner Pope Investments (TPI) Limited -
Broker
James Pope / Andrew
Thacker
|
+44 (0) 20 3657
0050
|
About Aptamer Group plc
Aptamer Group develops custom affinity binders
through its proprietary Optimer® platform to enable new
approaches in therapeutics, diagnostics, and research applications.
The Company strives to deliver transformational solutions that meet
the needs of life science researchers and
developers.
Optimer binders are oligonucleotide
affinity ligands that can function as an antibody alternative. The
global affinity ligand market is currently worth over $170
billion.
Aptamer has successfully delivered
projects for a range of global pharma companies, diagnostic
development companies, and research institutes, covering multiple
application areas with the objective of establishing
royalty-bearing licenses.